Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 11/20 | 0.69 |
| ▸ | TLR7 | Q9NYK1 | 5/20 | 0.69 |
| ▸ | KMO | O15229 | 1/20 | 0.46 |
| ▸ | MKNK1 | Q9BUB5 | 7/20 | 0.45 |
| ▸ | MKNK2 | Q9HBH9 | 7/20 | 0.45 |
| ▸ | PIM1 | P11309 | 1/20 | 0.44 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1238468 | 0.86 | TLR8 (0.67) | TLR8TLR7 | |
| SCHEMBL1235954 | 0.85 | TLR8 (0.51) | TLR8TLR7 | |
| SCHEMBL12619278 | 0.84 | TLR8 (0.72) | TLR8TLR7MKNK1MKNK2 | |
| SCHEMBL1801546 | 0.82 | TLR8 (1.00) | TLR8TLR7 | |
| SCHEMBL18772032 | 0.80 | TLR8 (0.56) | TLR8TLR7MKNK1MKNK2 | |
| SCHEMBL1237447 | 0.80 | TLR8 (0.48) | TLR8TLR7 | |
| SCHEMBL1238132 | 0.79 | TLR8 (0.73) | TLR8TLR7 | |
| SCHEMBL27078698 | 0.78 | TLR8 (0.42) | TLR8TLR7 | |
| SCHEMBL18771965 | 0.77 | TLR8 (0.53) | TLR8TLR7MKNK1MKNK2 | |
| SCHEMBL8195020 | 0.76 | TLR8 (0.42) | TLR8TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3159337-A2 | SUBSTITUTED BENZOAZEPINES AS TOLL-LIKE RECEPTOR MODULATORS | Ventirx Pharmaceuticals, Inc. (US) | 2017-04-26 | — | — | EP | disclosed |
| EP-2467380-B1 | SUBSTITUTED BENZOAZEPINES AS TOLL-LIKE RECEPTOR MODULATORS | VENTIRX PHARMACEUTICALS INC (US) | 2016-11-30 | — | — | EP | disclosed |
| US-20160137608-A1 | SUBSTITUTED BENZOAZEPINES AS TOLL-LIKE RECEPTOR MODULATORS | VENTIRX PHARMACEUTICALS, INC. (US) | 2016-05-19 | — | — | US | disclosed |
| US-9242964-B2 | Substituted benzoazepines as toll-like receptor modulators | VENTIRX PHARMACEUTICALS, INC. (US) | 2016-01-26 | — | — | US | disclosed |
| US-20140142086-A1 | Substituted Benzoazepines as Toll-Like Receptor Modulators | ARRAY BIOPHARMA, INC. (US) | 2014-05-22 | — | — | US | disclosed |
| US-8524702-B2 | Substituted benzoazepines as toll-like receptor modulators | VENTIRX PHARMACEUTICALS, INC. (US) | 2013-09-03 | — | — | US | disclosed |
| EP-2467380-A2 | SUBSTITUTED BENZOAZEPINES AS TOLL-LIKE RECEPTOR MODULATORS | Ventirx Pharmaceuticals, Inc. (US) | 2012-06-27 | — | — | EP | disclosed |
| US-20110118235-A1 | SUBSTITUTED BENZOAZEPINES AS TOLL-LIKE RECEPTOR MODULATORS | VENTIRX PHARMACEUTICALS, INC. (US) | 2011-05-19 | — | — | US | disclosed |
| WO-2011022509-A2 | SUBSTITUTED BENZOAZEPINES AS TOLL-LIKE RECEPTOR MODULATORS | VENTIRX PHARMACEUTICALS, INC. (US) | 2011-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160137608-A1 | SUBSTITUTED BENZOAZEPINES AS TOLL-LIKE RECEPTOR MODULATORS | TLR8, TLR1, TLR7 | TLR8 1/4885TLR7 3/4885KMO 164/4885 |
| US-20110118235-A1 | SUBSTITUTED BENZOAZEPINES AS TOLL-LIKE RECEPTOR MODULATORS | TLR8, TLR1, TLR7 | TLR8 1/4885TLR7 3/4885KMO 164/4885 |
| US-20140142086-A1 | Substituted Benzoazepines as Toll-Like Receptor Modulators | TLR8, TLR1, TLR7 | TLR8 1/4885TLR7 3/4885KMO 164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.